$ZBH (Zimmer Biomet Holdings, Inc.)

$ZBH {{ '2016-07-28T18:29:19+0000' | timeago}} • Webcast

$ZBH said in 2Q16 it released a series of next-generation enhancements to its OSS or Orthopedic Salvage System, advancing this unique solution for salvage revision procedures and oncologic applications. In 2H16, the company expects to further leverage the commercial opportunities of its knee portfolio for ongoing growth of this important category.

$ZBH {{ '2017-06-13T11:32:43+0000' | timeago}} • Announcement

Medical device company $ZBH announced that the U.S. FDA has notified the company about the closing out of its warning letter dated June 3, 2015 relating to its Zhejiang, China manufacturing facility. The company added that it will continue to take the necessary actions towards stricter quality control and regulatory compliance going forward.

$ZBH {{ '2017-05-30T21:28:38+0000' | timeago}} • Announcement

$ZBH's Board of Directors approved the payment of a quarterly cash dividend to stockholders for 2Q17. The cash dividend of $0.24 per share will be paid on or about July 28, 2017 to stockholders of record on June 23, 2017.

$ZBH {{ '2017-03-01T15:01:11+0000' | timeago}} • Announcement

$ZBH BoD has approved a quarterly cash dividend for 1Q17. The dividend of $0.24 per share will be paid on or about April 28, 2017 to stockholders of record as on March 31, 2017.

$ZBH {{ '2017-02-02T16:22:10+0000' | timeago}} • Announcement

$ZBH said the U.S. Food and Drug Administration (FDA) approved an expanded 26-week efficacy claim for its single-injection viscosupplement Gel-One Cross-linked Hyaluronate for the treatment of knee pain associated with osteoarthritis.

$ZBH {{ '2017-01-31T17:58:23+0000' | timeago}} • Webcast

During 4Q16, $ZBH continued to make progress towards enhancing and improving its supply chain and manufacturing and quality systems. The company anticipates continued progress towards the replenishment of safety stocks on key cross-sell products throughout 1H17, which will accelerate top line growth during 2H17.

$ZBH {{ '2017-01-31T17:50:45+0000' | timeago}} • Webcast

Healthcare company $ZBH said that it has made strategic investments throughout 2016 to broaden and diversify its musculoskeletal portfolio, including the introduction of more than 50 new clinical technology solutions and services.

$ZBH {{ '2017-01-31T15:39:40+0000' | timeago}} • Announcement

$ZBH expects constant currency revenue for FY17 to increase by approx. 3.7-4.7%. $ZBH expects foreign currency translation to decrease revenues by approx. 1.5%.  Therefore, revenue is expected to be in a range of $7.855-7.930Bil. The Company expects its FY17 diluted EPS to be in a range of $4.37-4.67.

$ZBH {{ '2017-01-31T15:35:34+0000' | timeago}} • Announcement

$ZBH reported lower 4Q16 earnings. Net earnings during the quarter fell 47.5% to $66.6MM from $127MM during 4Q15. Diluted EPS fell 46.8% to $0.33 from $0.62 during 4Q15. Net sales rose 4.1% YoverY to $2Bil. Excluding items, $COH earned $2.14 per share.

$ZBH {{ '2017-01-17T13:23:47+0000' | timeago}} • Announcement

$ZBH implemented a leadership transition that capitalizes on the strength of the its management team. Effective Jan. 23, 2017, Robert Delp will assume the position of President, Americas and join the executive leadership team of the company. Stuart Kleopfer has decided to retire from his position as President, Americas.

$ZBH {{ '2017-01-12T20:36:06+0000' | timeago}} • Announcement

$ZBH concluded agreements with the U.S. Department of Justice and the U.S. Securities and Exchange Commission to resolve the U.S. Foreign Corrupt Practices Act (FCPA) matters involving Biomet as well as in relation to former deferred prosecution agreement and consent to final judgment that Biomet entered into with DOJ and SEC, on March 26, 2012.

$ZBH {{ '2017-01-10T13:09:46+0000' | timeago}} • Announcement

$ZBH expects 2016 net sales of $7.684Bil, up 28.1% from last year. On an adjusted constant currency basis, $ZBH sees revenue to increase by 3.4%. Excluding contribution from the LDR Holding transaction, revenue rose by 2.3% on an adjusted constant currency basis. $ZBH now sees adjusted EPS to be towards upper end of prior estimate of $7.90-7.95.

$ZBH {{ '2017-01-10T13:06:47+0000' | timeago}} • Announcement

$ZBH expects 4Q16 net sales of about $2.013Bil, an increase of 4.1% over last year. On adjusted constant currency basis, revenue increased by 4.4%. Excluding the contribution from the LDR transaction and adjusting for one less billing day in the quarter, $ZBH estimates that revenues increased 3.5% over 4Q15.

$ZBH {{ '2016-12-19T12:45:06+0000' | timeago}} • Announcement

$ZBH BoD approved a quarterly cash dividend for 4Q16 of $0.24 per share, payable on or about Jan. 27, 2017 to stockholders of record as of the close of business on Dec. 30, 2016.

$ZBH {{ '2016-12-06T20:15:45+0000' | timeago}} • Announcement

$ZBH priced an offering of EUR 500MM of its 1.414% senior unsecured notes due 2022 and EUR 500MM of 2.425% senior unsecured notes due 2026. The closing is expected to occur on Dec. 13, 2016. The notes will pay interest on an annual basis. The joint book-running managers for the offering are BNP Paribas, HSBC Bank plc and RBC Europe Limited.

$ZBH {{ '2016-11-21T15:54:52+0000' | timeago}} • Announcement

$ZBH commences cash tender offers for up to $1.1Bil aggregate of its 5.75% senior notes due 2039, its 4.45% senior notes due 2045, its 4.25% senior notes due 2035, its 3.55% senior notes due 2025 and its 4.625% senior notes due 2019. The purpose of the offers is to reduce the principal amount of the company's outstanding debt securities.

$ZBH {{ '2016-11-15T17:57:59+0000' | timeago}} • Announcement

$ZBH announced positive update on biologics pipeline following preliminary analysis of data from the first pivotal trial of stem cell therapy for critical limb ischemia to reach completion. The trial is the first pivotal study of its kind to complete enrollment and 1-year follow-up in a challenging patient population with a high mortality risk.

$ZBH {{ '2016-10-31T12:34:43+0000' | timeago}} • Webcast

$ZBH's knee business was flat on a global basis in 3Q16, reflecting positive volume and mix of 1.9% and negative price of 2%. Hip business grew by 0.6%, reflecting positive volume and mix of 3% and negative price of 2.4%.

$ZBH {{ '2016-10-31T12:31:22+0000' | timeago}} • Webcast

$ZBH said it expects 4Q16 revenue to be in the range of $1,960-1,980MM. Adjusted diluted EPS is expected to be in the range of $2.08-2.13 per share.

$ZBH {{ '2016-10-31T11:51:50+0000' | timeago}} • Announcement

$ZBH estimates FY16 revenue to be in the range of $7.630-7.650Bil, up about 27% on a reported basis, from a year ago. FY16 diluted EPS is expected to be in the range of $1.50-1.60, and $7.90-7.95 on an adjusted basis.

$ZBH {{ '2016-10-31T11:51:29+0000' | timeago}} • Announcement

$ZBH posted 3Q16 net earnings of $158.8MM or $0.78 per share, up 612.5% from a year ago. This performance was helped by further acceleration of global S.E.T. category, as well as continued strength in the Asia Pacific region, the company said. Net sales were $1.83Bil, up 4% from a year ago.

Recent Transcripts

ARNC (Arconic Inc.)
Monday, July 24 2017 - 2:00pm
ISRG (Intuitive Surgical, Inc.)
Thursday, July 20 2017 - 8:30pm
LTXB (LegacyTexas Financial Group Inc.)
Wednesday, July 19 2017 - 1:00pm
MDT (Medtronic plc)
Thursday, May 25 2017 - 12:00pm
BABA (Alibaba Group Holding Limited)
Thursday, May 18 2017 - 11:30am
VCEL (Vericel Corporation)
Wednesday, May 10 2017 - 12:00pm
ATHX (Athersys, Inc.)
Tuesday, May 9 2017 - 8:30pm
XRAY (DENTSPLY International Inc.)
Tuesday, May 9 2017 - 12:30pm
ENDP (Endo International plc)
Tuesday, May 9 2017 - 12:30pm
MTD (Mettler-Toledo International Inc.)
Thursday, May 4 2017 - 9:00pm
MTD (Mettler-Toledo International Inc.)
Thursday, May 4 2017 - 12:00pm
FIT (Fitbit Inc.)
Wednesday, May 3 2017 - 9:00pm
MASI (Masimo Corporation)
Wednesday, May 3 2017 - 8:30pm
IDXX (IDEXX Laboratories, Inc.)
Friday, April 28 2017 - 12:30pm
ZBH (Zimmer Biomet Holdings, Inc.)
Thursday, April 27 2017 - 12:00pm
ARNC (Arconic Inc.)
Tuesday, April 25 2017 - 9:00pm
NUVA (NuVasive, Inc.)
Tuesday, April 25 2017 - 8:30pm
LTXB (LegacyTexas Financial Group Inc.)
Wednesday, April 19 2017 - 1:00pm
ISRG (Intuitive Surgical, Inc.)
Tuesday, April 18 2017 - 8:30pm
LW (Lamb Weston Holdings, Inc.)
Thursday, April 6 2017 - 2:00pm

AlphaGraphics you may like